This follows the commencement of trial runs and validation process at its 100 per cent subsidiary, Suven Synthesis, a US Food and Drugs Administration-compliant plant in the outskirts of Hyderabad.
The company hopes to get US FDA approval for the plant by the year end and has filed its first drug master file with US FDA during this month.
